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Abstract
Clostridium difficile infection is a frequent complication of antibiotic therapy in hospitalised patients,
which today is attracting more attention than ever and has led to its classiﬁcation as a ‘superbug’. Dis-
ruption of the composition of the intestinal microﬂora following antibiotic treatment is an important
prerequisite for overgrowth of C. difficile and the subsequent development of an infection. Treatment
options for antibiotic-associated diarrhoea and C. difficile-induced colitis include administration of spe-
ciﬁc antibiotics (e.g. vancomycin), which often leads to high relapse rates. More importantly, both the
rate and severity of C. difficile–associated diseases are increasing, with new epidemic strains of C. difficile
often implicated. For the prevention and treatment of antibiotic-associated diarrhoea and C. difficile
infection, several probiotic bacteria such as selected strains of lactobacilli (especially Lactobacillus
rhamnosus GG), Bifidobacterium longum, and Enterococcus faecium and the non-pathogenic yeast
Saccharomyces boulardii have been used. Controlled trials indicate a beneﬁt of S. boulardii and L. rhamnosus
GG as therapeutic agents when used as adjuncts to antibiotics. However, the need for more well-
designed controlled trials with probiotics is explicit.
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1. Introduction
Clostridium difficile is a ubiquitous anaerobic, sporulating,
Gram-positive, rod-shaped bacterium that is isolated from
both soil and living organisms, including humans (Smith
and King 1962; Alpern and Dowell 1971; Hafiz et al.
1975; Hafiz and Oakley 1976; Borriello et al. 1983). One
of the primary habitats for C. difficile is the gut of infants
(Levett 1986). Prevalence rates of 46% have been reported
in healthy infants under 12 months old, and colonisation
rates of up to 55% have been reported in neonatal inten-
sive care units (Donta and Myers 1982). Although in
many infants faecal cytotoxic titres are extremely high
and similar to those seen in adults with pseudomembra-
nous colitis (PMC), infants show no obvious symptoms
(Cooperstock and Zedd 1983). However, they are not
resistant to the disease as a result of selective colonisation
with non-toxigenic strains. In healthy adults, prevalence
rates are rare at 3–5% (Viscidi et al. 1981), and in hospi-
tal in-patients rates are 16–35% (McFarland et al. 1989).
The reasons for high colonisation rates with no symptoms
in infants and low rates in adults are not clear.
2. Importance of C. difficile in human infections
In 1935, Hall and O’Toole isolated C. difficile from the
stools of healthy newborn infants and showed strains to be
toxigenic. However, the bacterium was not associated with
intestinal disease until the late 1970s. Antibiotic-associated
diarrhoea (AAD) is defined as diarrhoea developing
from a few hours after the onset of antibiotic therapy to
6–8 weeks following antibiotic discontinuation (Bartlett
1992; Hogenauer et al. 1998). The incidence of AAD in
the literature varies from 5–25% in patients receiving anti-
biotics, depending on the class of antibiotic used and con-
founding risk factors in the patients being treated (Bartlett
et al. 1978a; Hove et al. 1996; McFarland 1998). After
1950 and with the development of broad spectrum antibio-
tics, AAD became a recognised condition. However, it
was in 1978 with the emergence of PMC occurring in
patients treated with clindamycin, that C. difficile was
identified as a serious aetiological agent (Bartlett et al.
1978a, 1978b; George et al. 1978).
3. Pathogenesis of AAD
During most courses of antibiotic therapy, alteration of the
normal flora of the bowel leads to a loss of equilibrium
and consequently of the resistance to colonisation, which
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may result in the emergence of pathogenic organisms such
as C. difficile (Hogenauer et al. 1998). Disruption of the
ecological equilibrium of the normal intestinal microflora
may result in diarrhoea associated with alteration of fer-
mentation processes and a reduction in short-chain fatty
acids (‘functional diarrhoea’). The most important bacter-
ial aetiology of AAD is C. difficile (Hove et al. 1996).
3.1 C. difficile and AAD
Since the demonstration of the role of this organism in
PMC (Bartlett et al. 1978b; George et al. 1978), its impor-
tance has grown significantly over the last 30 years. The
levels of C. difficile in AAD were demonstrated to be 20–
25%, with over 95% of PMC involving the microorganism
(Hogenauer et al. 1998; McFarland et al. 1999; Bartlett
2002).
3.2 C. difficile virulence factors
The pathogenesis of PMC is mediated by two potent,
heat-labile cytotoxic toxins produced by C. difficile: toxin
A, which is an enterotoxin, and toxin B, a cytotoxin
(Lyerly et al. 1988; Pothoulakis and Lamont 2001). Toxin
A has a molecular mass of 308 kDa whereas toxin B has
a molecular of 279 kDa (Barroso et al. 1990; Dove et al.
1990). The amino acid sequences of the toxins show a
high level of homology (von Eichel-Streiber et al. 1990,
1992).
Both toxins are capable of inflicting significant damage
to the human colonic epithelium, including modulating
fluid secretion and inducing a necrotic inflammatory
response, and they act synergistically in this (Savidge
et al. 2003). A large range of clinical presentations have
been reported, from an asymptomatic carriage to fulminant
colitis, depending on the potential overgrowth of the
organism. Recent work has revealed the cellular mechan-
ism of action of the toxins (see Figure 1). Both toxins A
and B have monoglycosyltransferase activity, which cata-
lyses the incorporation of glucose into a variety of sub-
strate proteins (Just et al. 1995a, 1995b, 1995c). These
include the small GTP-binding proteins (Rho, Rac and
Cdc42Hs) that are involved in the regulation of the actin
cytoskeleton, specifically in the formation of actin stress
fibres and focal adhesions. In the diseased state, the colo-
nic epithelium is the major target of C. difficile toxins.
They cause disruption of the barrier function by opening
the tight junctions. This effect is not only caused by the
breakdown of actin filaments, but also by inactivation of
Rho’s ability to regulate tight junction complexes. These
barrier-disrupting effects of toxins A and B increase the
colonic permeability, the basis of watery diarrhoea, which
is a typical feature of C. difficile AAD (Poxton et al.
2001). The colitis is characterised by a massive influx of
neutrophils into the colonic mucosa, and in PMC there
is an acute inflammatory infiltrate with microabscesses
and pseudomembranes rich in neutrophils (Souza et al.
1997).
3.3 Pathogenesis of alterations in the function of the
intestinal flora
The normal production of lactic acid and short-chain fatty
acids (acetate, butyrate, propionate) by the anaerobic flora
in AAD is decreased due to diminished digestion of carbo-
hydrates, which results in functional disturbances of the
colonic mucosa (Hove et al. 1996; Hogenauer et al.
1998). Moreover, diminished or suppressed carbohydrate
metabolism may result in osmotic diarrhoea (‘overload
mechanism’) and poor absorption of short-chain fatty
acids (‘underload mechanism’; Clausen et al. 1991; Gus-
tafsson et al. 1998), water and electrolytes (cations bound
by anionic organic acids; Hammer et al. 1990). Decreased
bile acid dehydroxylation, a process that is performed nor-
mally by bacteria in the colon (Takamine and Imamura
1995), has been also advocated among the metabolic dis-
turbances resulting from antibiotic use (Hofmann 1977).
3.4 Complications
One of the most frequent complications in hospital
patients with C. difficile-associated diarrhoea is the fre-
quency of relapse (McFarland et al. 1999). This recurrent
form of AAD leads to increased use of antibiotics (vanco-
mycin), extended hospital stays and medical complica-
tions. C. difficile-associated disease (CDAD) causes death
in 1–2% of affected patients, whereas the mortality rate
increases to 6–30% when PMC is present (Miller et al.
2002; Aslam et al. 2005).
3.5 Epidemiology and risk factors
Two main types of predisposing factors have been recog-
nised in AAD: the class of antibiotic administered, and
host factors (age and underlying pathologies). Other envir-
onmental circumstances may also contribute towards the
spread of PMC.
3.5.1 Antibiotic class
Nearly all antibiotics have been reported to be associated
with AAD and CDAD, provided that antibiotic concentra-
tions are high enough in the intestinal lumen to inhibit the
anaerobes (Wistrom et al. 2001). The most commonly
implicated are clindamycin, aminopenicillins (ampicillin/
amoxicillin), a combination of amoxicillin and clavulanic
acid, second or third generations of cephalosporins (cefur-
oxime, cefotaxime, ceftazidime, ceftriaxone) and, more
recently, fluoroquinolones (Johnson et al. 1999; Wistrom
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et al. 2001; McCusker et al. 2003; Loo et al. 2005; Muto
et al. 2005; Pepin et al. 2005b). In hospitals, the incidence
of AAD is highest in intensive care unit (ICU) patients,
with the duration of use of the inciting antibiotic therapy
an additional risk factor (Wistrom et al. 2001). In addi-
tion, proton pump inhibitors have been implicated as a
further possible risk factor (Cunningham et al. 2003; Dial
et al. 2004, 2005, 2006; Yearsley et al. 2006).
3.5.2 Host factors
ICU patients with severe underlying pathologies, such as
elderly or immunosuppressed patients, or those that have
undergone surgical (transplant, gastrointestinal) procedures
or that have nasogastric feed tubing, show the highest
incidence of AAD and PMC (Brown et al. 1990). While
approximately 70% of the population have serum antibo-
dies against toxin A and/or B, the presence of basal levels
of antibodies in inpatients exposed to C. difficile is not
protective against colonisation (Kyne et al. 2000; Johal
et al. 2004). Patient age is one risk factor, with a higher
incidence of colonisation at the extreme ages of life (<6
and >65 years old: Brown et al. 1990; Ackermann et al.
2005).
3.5.3 Environmental factors
A hospital offers multiple opportunities for gastrointest-
inal, nosocomial infections, and the spread of C. difficile
between patients has been well-documented (Wistrom
et al. 2001). C. difficile is considered a nosocomial organ-
ism (Bartlett 2002) and gut surgery and gastrointestinal
exploratory procedures increase the risk of AAD (Acker-
mann et al. 2005).
3.6 Treatments of AAD
3.6.1 Mild or moderate cases of AAD
Asymptomatic carriers of C. difficile should not be treated
(Johnson et al. 1992). Treatments for AAD comprise con-
ventional measures such as rehydration and discontinua-
tion of the inciting agent, or replacement of the latter if
necessary by a more appropriate antibiotic.
3.6.2 Antibiotic therapy in severe AAD:
treatment of PMC
Severe cases of AAD related to C. difficile require a suita-
bly adapted oral antibiotic therapy. The recommended
Figure 1. Mechanism of action of Clostridium difficile toxins A and B on the intestinal epithelium. Both toxins modify
small proteins (GTP-binding proteins) that regulate the actin cytoskeleton by incorporating a glucose molecule into them.
The toxins then cause disruption of the barrier function of the intestinal epithelium by opening the tight junctions and
increasing colonic permeability. This is because GTPases regulate tight junction complexes. The immune response
is characterised by a massive influx of neutrophils. Reproduced with permission from Ian R. Poxton, University of
Edinburgh, UK.
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antibacterial agents are metronidazole, which constitutes
first-line therapy (Gerding 2005; Modena et al. 2006), and
vancomycin (Teasley et al. 1983). Agents used less fre-
quently include bacitracin (Young et al. 1985), teicoplanin
and fusidic acid (Wenisch et al. 1996; Wullt and Odenholt
2004). However, relapses have been reported in all cases
(Fernandez et al. 2004; Musher et al. 2005; Pepin et al.
2005a). Moreover, there is concern regarding the selection
of vancomycin-resistant organisms, mainly Enterococcus
faecium, which is a promiscuous microorganism with
respect to the transfer of antibiotic resistance (ASHP
1998).
4. Changes in C. difficile epidemiology
Historically, low rates of severe disease and death (3%)
may have led to an underestimation of the importance of
CDAD as an infection linked to health care (Rubin et al.
1995). Nevertheless, each case of CDAD has been esti-
mated to result in more than $3600 of health care costs,
and these costs exceeded $1 billion in the US in 2002
(Kyne et al. 2002). Both the rate and the severity of
CDAD may be increasing in US health care facilities. An
analysis of data from the National Nosocomial Infections
Surveillance system identified an increase in rates from
the late 1980s through to 2001 (Archibald et al. 2004).
The epidemiology of C. difficile is changing, as docu-
mented in many recently published articles (Pepin et al.
2004). Researchers from the US and Canada note
increased rates of CDAD and episodes of more serious
disease, both in hospitals and in the community (Pepin
et al. 2004). The risk factors for CDAD may also be chan-
ging. As noted recently in Europe, North American
researchers are also describing a new epidemic strain of
C. difficile named BI/NAP1, which is positive for binary
toxin and carries the virulence properties and antibiotic
resistance patterns of the European strain (ribotybe) O27.
Current BI/NAP1 strains are more resistant to fluoroquino-
lones than are historic isolates (McDonald et al. 2005).
Canadian researchers also documented it as the predomi-
nant strain in a multi-institutional outbreak in the Quebec
area. In a prospective study of CDAD in 1703 patients at
12 hospitals in Quebec, Loo et al. (2005) linked the epi-
demic strain to an increased incidence of C. difficile from
5–6 cases per 1000 admissions to about 25 per 1000
admissions. They also reported that the 30 day mortality
rate attributable to infection was 6.9%. The strain was also
resistant to fluoroquinolines (Loo et al. 2005).
Community-based cases are also changing. Recently, in
the Morbidity and Mortality Weekly Report, four state
health departments in the US reported on 33 unusual cases
of community-based CDAD that had occurred between
2003 and the middle of 2005 (Anon. 2005). The cases were
unusual as disease was severe and involved peripartum
women and healthy individuals who had not been recently
hospitalised, including eight who had no history of recent
antibiotic use.
5. Rationale for living microorganisms
(probiotics) in the treatment or prevention
of AAD
The human normal intestinal flora is formed of up to 1012
bacteria per gram of intestinal content and consists of
more than 1000 species (Berg 1996; Suau et al. 1999;
Vaughan et al. 2000; Hughes et al. 2001; Blaut et al.
2002; Guarner and Malagelada 2003; Xu and Gordon
2003). Aerobic, facultative and anaerobic bacteria inhabit
the gastrointestinal tract. The proportion of anaerobic bac-
teria increases from the proximal to distal regions, and
99% of inhabitants located in the large intestine are anae-
robes. Despite the complexity of the gut bacterial popula-
tion, its gross composition is remarkably stable and tends
to be characteristic for each individual (Zoetendal et al.
1998, 2001; Mai et al. 2004; Vanhoute et al. 2004). All of
these bacteria form a stable ecosystem together with the
intestinal mucosa (Guarner and Malagelada 2003). The
equilibrium of the ecosystem is affected by specific niches
for individual bacterial populations, and cooperation in
terms of the metabolism of various substrates and cross-
feeding between bacteria (Belenguer et al. 2006). There-
fore, one important property of this stable ecosystem is
colonisation resistance, which permits the elimination of
exogenous microorganisms. However, any antibiotic ther-
apy may alter the normal equilibrium of the intestinal
microflora, hence encouraging the potential for pathogenic
organisms to emerge and cause abnormal growth of C. dif-
ficile (Johnson et al. 1999; Wistrom et al. 2001; Pepin
et al. 2005b). The hypothesis that living microorganisms
could be administered for treatment or prevention of AAD
has been supported by the administration of several ‘phy-
siological’ non-pathogenic organisms (Table 1). These
have been designated ‘probiotics’ (Cremonini et al.
2002b; Szajewska et al. 2006) or ‘biotherapeutic agents’
(Elmer et al. 1996; Roffe 1996), and defined as ‘‘living
microbial supplements that exert a beneficial effect on the
host by improving the intestinal ecosystem’’. Most of
these probiotics are bacteria or yeasts used clinically in
lyophilised form, and are commercially available.
5.1 Probiotics in the prevention and treatment
of AAD
Both bacteria and yeast have been used in the treatment
and prevention of AAD, as well as the prevention of asso-
ciated diarrhoea and reduced relapse (Table 1).
Lactobacillus rhamnosus GG was administered in the
form of a yoghurt for 1 week prior to administration of
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erythromycin (400 mg three times/day). This resulted in a
diminished duration of diarrhoea in 16 patients compared
to a placebo group (2 vs. 8 days; p < 0.05) and C. difficile
toxin was negative in all 16 patients at the end of the
treatment period (Siitonen et al. 1990). In 38 paediatric
patients with amoxicillin-induced diarrhoea the administra-
tion of a mixture of Lactobacillus acidophilus and Lacto-
bacillus bulgaricus, four times a day for 10 days together
with the antibiotic therapy, had no preventative effect on
diarrhoea (Tankanow et al. 1990). Stool samples were not
tested for C. difficile (culture and/or toxin). However, in a
randomised placebo-controlled cross-over study in 10
healthy volunteers receiving erythromycin (3 days, 1 g
twice/day), oral ingestion of yoghurt containing Bifidobac-
terium longum significantly diminished the number of
stools (double in the placebo group but unchanged in the
yoghurt group) and degree of abdominal pain compared to
volunteers receiving placebo-yoghurt (Colombel et al.
1987). Stool samples were not tested for C. difficile (cul-
ture and/or toxin). In 188 children (6 months to 10 years
old) treated with antibiotics, administration of Lactobacil-
lus GG (1–2 capsules a day, 1010 CFU per capsule)
resulted in a significant difference in the occurrence of
diarrhoea (16 out of 93 children) compared to the placebo
group (46 out of 95 children, p < 0.0001; Young et al.
1998). In a recent double-blind, randomised, placebo-
controlled trial, 150 elderly patients received standard
antibiotic treatment plus 2  1010 CFU L. acidophilus and
Bifidobacterium bifidum/capsule per day for 20 days. On
the basis of the development of diarrhoea, the incidence
of samples positive for C. difficile-associated toxins was
2.9% in the probiotic group vs. 7.25% in the placebo
group. When samples from all patients were tested, 46%
of probiotic patients were toxin-positive compared with
78% of the placebo group (Plummer et al. 2004).
E. faecium SF68 has shown only modest efficacy in the
prevention of AAD in two controlled clinical trials. Forty-
five patients being treated with antibiotics were given,
concurrently, one capsule twice daily of either E. faecium
SF68 (7.5  107 CFU) or placebo for 7 days. The rate of
AAD was 9% with SF68 compared with a placebo rate of
27% (Wunderlich et al. 1980). In the second study (not
double-blind), 200 patients received antituberculic antibio-
tics. Patients administered orally with E. faecium SF68
showed a lower rate (5%) of AAD compared to the pla-
cebo group (18%; Borgia et al. 1982).
In 388 ambulatory patients with upper respiratory tract
infections receiving tetracycline or b-lactams for longer
than 5 days, Saccharomyces boulardii reduced the preva-
lence of AAD to 4.5% compared to 17.5% in the placebo
group (p < 0.001; Adam et al. 1977). Stool samples were
not tested for C. difficile (culture and/or toxin). In a dou-
ble-blind, placebo-controlled study with 180 patients
receiving any antibiotic except vancomycin or metronida-
zole, the occurrence of AAD was limited to 9.5% in
patients treated with S. boulardii compared to 22% in the
placebo group (Surawicz et al. 1995). Stool samples were
also tested for C. difficile (culture and toxin). Similarly, in
193 patients receiving b-lactam antibiotics, the administra-
tion of S. boulardii (1 g daily for 2 weeks) in addition to
antibiotics, resulted in a lower incidence of AAD (7.2% of
patients receiving S. boulardii compared to 14.6% in the
placebo group, p = 0.02; McFarland et al. 1995). Simulta-
neous administration is possible because of its resistance
to most antibiotics (Bergogne-Berezin 1995). However,
Lewis et al. (1998) reported a lack of a therapeutic effect
with S. boulardii (113 mg twice daily) in the prevention
of AAD in a placebo-controlled study with 72 elderly
patients. The lack of effect was attributed to the low dose
used. However, in a recent double-blind, randomised pla-
cebo-controlled trial of 269 children (aged 6 months to
14 years) with otitis and/or respiratory tract infections,
standard antibiotic treatment together with 250 mg of
S. boulardii orally twice daily resulted in a lower preva-
lence of diarrhoea than in those receiving antibiotic plus
placebo (8 vs. 23%). In a separate study, the occurrence of
AAD was also limited to 3.4% in patients treated with S.
boulardii compared to 17.3% in the placebo group
(Kotowska et al. 2005). One hundred and fifty-one patients
hospitalised at the Gulhane Military Medical Academy’s
Department of Infectious Diseases and Clinical Microbiol-
ogy were given S. boulardii twice daily during the course
of antibiotic therapy. Patients did not require intensive care
therapy and application was initiated as late as 48 h after
antibiotic therapy. The rate of development of AAD was
found to be 9% (7/78) in the placebo group was and 1.4%
(1/73) in the study group (p < 0.05). Stool samples from
the patients with AAD were assayed for C. difficile toxin A
as late as 7 days after the collection of samples. The assay
for C. difficile toxin A yielded positive results in two stool
samples from the seven patients with AAD in the placebo
group and a negative result was obtained for the one
patient who developed AAD in the study group. The
results implied that prophylactic use of S. boulardii in hos-
pitalised patients resulted in a reduced incidence of AAD,
with no serious side effects seen (Can et al. 2006).
5.2 Probiotics in the prevention and treatment
of CDAD
Early uncontrolled trials of Lactobacillus rhamnosus GG
suggested a possible efficacy in recurrent CDAD. In four
different studies, 8 out of 11 adults (Gorbach et al. 1987),
two out of four children (Biller et al. 1995), five out of
nine adults (Bennett et al. 1990) and 27 out of 32 adults
(Bennett et al. 1996) demonstrated beneficial effects.
A single randomised, controlled trial using L. rhamnosus
GG with either metronidazole or vancomycin has been
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reported (Pochapin 2000). The recurrence rate was similar
for the probiotic (36.4%) and placebo groups (35.7%). A
small study of 20 patients with recurrent CDAD, metroni-
dazole and either Lactobacillus plantarum 299v (5  1010
CFU/day) or placebo were given for 38 days (Wullt et al.
2003). Although the recurrence rate was lower in the
L. plantarum group (36.4%) compared to the placebo
(66.7%), the difference was not significant. In 19 children
with persistent diarrhoea associated with the presence of
C. difficile in stools, S. boulardii administered as a mono-
therapy resulted in a significant improvement in symptoms
in 18 patients after 8 days of treatment (Buts et al. 1993).
In a double-blind, randomised, controlled study, S. boular-
dii versus placebo was given to 124 patients with C. dif-
ficile associated-diarrhoea, with a view of preventing
relapses. The number of relapses was significantly reduced
to 26% compared to the placebo group at 45% (p = 0.05).
The efficacy of S. boulardii in preventing relapses has
been shown more clearly in patients who had a previous
relapse of AAD. In these patients, relapses occurred in 35
vs. 65% (p = 0.04) in the placebo control (McFarland
et al. 1994). In an effort to further refine a standard regi-
men, the same group tested patients receiving a standard
antibiotic for 10 days and then added either S. boulardii
(1 g/day for 28 days) or placebo. A significant decrease in
the recurrence was observed only in patients treated with
high-dose vancomycin (2 g/day) and S. boulardii (17%),
compared to those who received high-dose vancomycin
and placebo (50%, p = 0.05). However, S. boulardii treat-
ment had no impact on the recurrence rates in patients
treated with a low dose of vancomycin or metronidazole
(Surawicz et al. 2000).
A recent clinical trial demonstrated that administration
of L. plantarum 299v reduced the negative effects of
metronidazole on colonic fermentation (Wullt et al. 2007).
The authors suggested that intake of L. plantarum 299v
affected concentrations of faecal organic acids during and
after metronidazole treatment in 19 patients with recurrent
C. difficile-associated diarrhoea. Following the intake of
metronidazole, a significant decrease in total short-chain
fatty acids was seen in the placebo group (from 77.1 to
45.5 mmol/g, p = 0.028), but no effect was seen in the
Lactobacillus group (79.8 to 60.4 mmol/g). In addition, a
statistically significant difference between treatment
groups was noted for butyrate (from 5.6 to 1.2 mmol/g in
the placebo group vs. 7.6 to 5.6 mmol/g in the Lactobacil-
lus group, p = 0.047). At the end of the study and after
cessation of placebo or Lactobacillus treatment, total
short-chain fatty acids rose to the same levels as those
recorded prior to the start of antibiotic treatment in the
placebo group. Therefore it is possible that intake of
this probiotic strain may provide an additional benefit
for patients with recurrent C. difficile-associated diar-
rhoea.
6. Conclusions
AAD and C. difficile are common clinical problems. The
concept of replacing disease-inducing pathogenic organ-
isms with non-pathogenic ones appears useful. The use of
probiotics in the control of gastrointestinal disorders offers
an alternative approach/adjunct to conventional antibiotic
therapies. Several live microorganisms have been used in
the treatment and prevention of AAD and CDAD. They
include L. rhamnosus GG, B. bifidum or yeasts such as
S. boulardii. The results discussed here show an overall
reduction in the risk of AAD during probiotic administra-
tion. The most reproducible results so far have been
achieved with S. boulardii and L. rhamnosus GG predomi-
nantly, both in terms of reducing the incidence of AAD
and the number of relapses in recurrent C. difficile-
associated diarrhoea. However, the number of clinical
trials with ‘biotherapeutic’ agents is limited, and one of
the main issues is inconsistency; many studies on AAD
have not tested for C. difficile (culture and/or toxins)
before or after treatment, the definition of diarrhoea within
the studies varies, the duration and the dose of treatment
varies as does the follow-up period, and the number of
patients and the design in many (early) studies is consid-
ered inadequate. Some theoretical considerations also arise
regarding the possibility of side-effects with ‘biothera-
peutic’ agents such as bacteraemia, especially in immuno-
suppressed patients. These concerns have, however, not
been confirmed by clinical experience. Therefore, further
well-designed, controlled clinical trials with standard defi-
nitions and fixed parameters need to be undertaken, using
various probiotic preparations for the treatment of confirmed
C. difficile diarrhoea. In conclusion, it would appear that
there is some merit in the probiotic approach to address
C. difficile-induced problems. Certainly, there is a need to
address the ubiquity and consequences of this pathogen.
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